acticor

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Show more

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Show more

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market, with €15.5 million raised

Show more

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Show more

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Show more

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Show more